Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,092 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Not listed No phase listed Observational

Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients

NCT02160366
View directory record Official record
Conditions
Advanced Cancers
Interventions
Biomarker Research
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

NCT01198028
View directory record Official record
Conditions
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 1 Interventional

Erlotinib in Combination With Cetuximab

NCT00895362
View directory record Official record
Conditions
Advanced Cancers
Interventions
Erlotinib, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 7, 2026, 6:33 PM EDT
Recruiting Not applicable Interventional

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

NCT05879159
View directory record Official record
Conditions
Liver
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

NCT04465162
View directory record Official record
Conditions
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Extranodal Marginal Zone Lymphoma
Interventions
Radiation Therapy
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 7, 2026, 6:33 PM EDT
Active, not recruiting Phase 2 Interventional

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

NCT04940299
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Bladder Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Carcinoma, Metastatic Urethral Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v6, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Withdrawn Phase 2 Interventional

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

NCT05535023
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
Interventions
SAR444245, Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 7, 2026, 6:33 PM EDT
Active, not recruiting Phase 2 Interventional

Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases

NCT03028337
View directory record Official record
Conditions
Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions
Spine Radiosurgery, Questionnaires
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Active, not recruiting Not applicable Interventional

An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer

NCT04871139
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biopsy, Contrast-Enhanced Mammography, Questionnaire Administration, Radioactive Iodine
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

NCT04426201
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 7, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

NCT05036681
View directory record Official record
Conditions
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
Interventions
Futibatinib, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 1 Interventional

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

NCT01787500
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions
Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Withdrawn Phase 2 Interventional

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00634894
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Femara, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

NCT00472056
View directory record Official record
Conditions
Lymphoma
Interventions
Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 7, 2026, 6:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

NCT05394337
View directory record Official record
Conditions
Metastatic Malignancy
Interventions
Atezolizumab, Tiragolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 2 Interventional

Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer

NCT00003677
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Dolastatin 10
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 7, 2026, 6:33 PM EDT
Recruiting No phase listed Observational

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

NCT00477100
View directory record Official record
Conditions
Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
Interventions
Biospecimen Collection, Interview, Medical Chart Review, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Greeley, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

NCT00967044
View directory record Official record
Conditions
Lymphoma
Interventions
Panobinostat, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 7, 2026, 6:33 PM EDT
Completed No phase listed Observational

Pre-Surgical Qigong Therapy for Women With Breast Cancer

NCT00495209
View directory record Official record
Conditions
Breast Cancer
Interventions
Qigong
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 7, 2026, 6:33 PM EDT
Completed No phase listed Observational

Development of a Patient Decision Aid for Women Considering Breast Reconstruction

NCT04817709
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Educational Intervention, Usual Care, Media Intervention, Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 7, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

NCT04751409
View directory record Official record
Conditions
Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions
Chest Radiography, Computed Tomography, Follow-Up, Imaging Technique, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Recruiting No phase listed Observational

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

NCT03039439
View directory record Official record
Conditions
Parathyroid Gland Adenoma, Parathyroid Gland Atypical Adenoma, Parathyroid Gland Carcinoma, Primary Hyperparathyroidism
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Terminated Phase 1Phase 2 Interventional

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

NCT02392572
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Akt/ERK Inhibitor ONC201, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 7, 2026, 6:33 PM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

NCT04708067
View directory record Official record
Conditions
Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Bintrafusp Alfa, Biopsy, Hypofractionated Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 7, 2026, 6:33 PM EDT